Skip to main content
SpringerLink
Log in

Relation of hepcidin gene expression in blood mononuclear cells with iron overload severity among β-thalassemia major patients

  • Original Article
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Iron overload is the main cause of morbidity and mortality in β-thalassemia major patients, and cardiac iron overload is the most common reason for death in these transfusion-dependent patients. Hepcidin, a liver-derived peptide hormone, plays a key role in plasma iron levels regulation by controlling two main stages, digestive iron absorption in enterocytes, and iron recycling in macrophages. Although hepcidin is mainly secreted from hepatocytes in the liver, it is also synthesized from mononuclear cells consisting of monocytes and lymphocytes. Binding of this molecule to ferroportin, a specific cellular exporter of iron, leads to degradation of the ligand-receptor complex, which reduces the iron overload by lowering the amounts of iron released into the plasma. Likewise, the same mechanism has been proved to be true for lymphocyte-drived hepcidin. The expression levels of hepcidin mRNA were evaluated using quantitative real time PCR (qRT-PCR) in 50 β-thalassemia major patients, as well as 25 healthy volunteers as the group of control. There was a significantly positive correlation between the cardiac iron concentration, showed by higher T2 values, and hepcidin levels in the patients (p = 0.028; r = 0.311). However, hepcidin expression levels did not significantly correlate with ferritin and liver iron concentrations. Hepcidin can act as a beneficial marker to determine iron overload degrees, particularly in the heart, in β-thalassemia major patients and be used as a logical therapeutic agent for treatment of β-thalassemia disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Higgs DR, Engel JD, Stamatoyannopoulos G (2012) Thalassaemia. Lancet 379(9813):373–383

    CAS  PubMed  Google Scholar 

  2. De Sanctis V, Kattamis C, Canatan D, Soliman AT, Elsedfy H, Karimi M et al (2017) β-Thalassemia distribution in the old world: an ancient disease seen from a historical standpoint. Mediterr J Hematol Infect Dis 9(1):e2017018

    PubMed  PubMed Central  Google Scholar 

  3. Karimi M, Bonyadi M, reza Galehdari M, Zareifar S (2008) Termination of pregnancy due to thalassemia major, hemophilia, and down’s syndrome: the views of Iranian physicians. BMC Med Ethics 9(1):19

    PubMed  PubMed Central  Google Scholar 

  4. Ngim CF, Lai NM, Ibrahim H, Ratnasingam V (2013) Attitudes towards prenatal diagnosis and abortion in a multi-ethnic country: a survey among parents of children with thalassaemia major in Malaysia. J Community Genet 4(2):215–221

    PubMed  PubMed Central  Google Scholar 

  5. Rund D, Rachmilewitz E (2000) New trends in the treatment of β-thalassemia. Crit Rev Oncol Hematol 33(2):105–118

    CAS  PubMed  Google Scholar 

  6. Ghotbi N, Tsukatani T (2005) Evaluation of the national health policy of thalassaemia screening in the Islamic Republic of Iran. EMHJ-East Mediterr Health J 11(3):308–318

    CAS  Google Scholar 

  7. Pennell DJ, Udelson JE, Arai AE, Bozkurt B, Cohen AR, Galanello R et al (2013) Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation 128(3):281–308

    CAS  PubMed  Google Scholar 

  8. Krittayaphong R, Viprakasit V, Saiviroonporn P, Siritanaratkul N, Siripornpitak S, Meekaewkunchorn A et al (2017) Prevalence and predictors of cardiac and liver iron overload in patients with thalassemia: a multicenter study based on real-world data. Blood Cells Mol Dis 66:24–30

    CAS  PubMed  Google Scholar 

  9. Kemna EH, Tjalsma H, Willems HL, Swinkels DW (2008) Hepcidin: from discovery to differential diagnosis. Haematologica 93(1):90–97

    CAS  PubMed  Google Scholar 

  10. Nemeth E (2010) Hepcidin in β-thalassemia. Ann N Y Acad Sci 1202:31

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Ganz T (2011) Hepcidin and iron regulation, 10 years later. Blood 117(17):4425–4433

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Pratummo K, Jetsrisuparb A, Fucharoen S, Tripatara A (2014) Hepcidin expression from monocyte of splenectomized and non-splenectomized patients with HbE-β-thalassemia. Hematology 19(3):175–180

    CAS  PubMed  Google Scholar 

  13. Pinto JP, Dias V, Zoller H, Porto G, Carmo H, Carvalho F et al (2010) Hepcidin messenger RNA expression in human lymphocytes. Immunology 130(2):217–230

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S (2006) Suppression of hepcidin during anemia requires erythropoietic activity. Blood 108(12):3730–3735

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM et al (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306(5704):2090–2093

    CAS  PubMed  Google Scholar 

  16. Aschemeyer S, Qiao B, Stefanova D, Valore EV, Sek AC, Ruwe TA et al (2018) Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin. Blood 131(8):899–910

    PubMed  PubMed Central  Google Scholar 

  17. Evstatiev R, Gasche C (2012) Iron sensing and signalling. Gut 61(6):933–952

    CAS  PubMed  Google Scholar 

  18. Pasricha S-R, Frazer DM, Bowden DK, Anderson GJ (2013) Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study. Blood 122(1):124–133

    CAS  PubMed  Google Scholar 

  19. Wrighting DM, Andrews NC (2006) Interleukin-6 induces hepcidin expression through STAT3. Blood 108(9):3204–3209

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Zhao N, Zhang A-S, Enns CA (2013) Iron regulation by hepcidin. J Clin Investig 123(6):2337–2343

    CAS  PubMed  Google Scholar 

  21. Kaddah AM, Abdel-Salam A, Farhan MS, Ragab R (2017) Serum hepcidin as a diagnostic marker of severe iron overload in beta-thalassemia major. Indian J Pediatr 84(10):745–750

    PubMed  Google Scholar 

  22. Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G et al (2007) Liver iron concentrations and urinary hepcidin in β-thalassemia. Haematologica 92(5):583–588

    CAS  PubMed  Google Scholar 

  23. Kaddah NA, El-Gindi HD, Mostafa NO, El-Aziz A, Nevin M, Kamhawy AH (2011) Role of hepcidin in the pathogenesis of iron overload in children with b-thalassemia. Int J Acad Res 3(4):62

    Google Scholar 

  24. Chauhan R, Sharma S, Chandra J (2014) What regulates hepcidin in poly-transfused β-thalassemia major: erythroid drive or store drive? Indian J Pathol Microbiol 57(1):39

    PubMed  Google Scholar 

  25. Camberlein E, Zanninelli G, Détivaud L, Lizzi AR, Sorrentino F, Vacquer S et al (2008) Anemia in β-thalassemia patients targets hepatic hepcidin transcript levels independently of iron metabolism genes controlling hepcidin expression. Haematologica 93(1):111–115

    CAS  PubMed  Google Scholar 

  26. El Beshlawy A, Alaraby I, Abdel Kader MS, Ahmed DH, Abdelrahman HE (2012) Study of serum hepcidin in hereditary hemolytic anemias. Hemoglobin 36(6):555–570

    PubMed  Google Scholar 

  27. Ravasi G, Pelucchi S, Trombini P, Mariani R, Tomosugi N, Modignani GL et al (2012) Hepcidin expression in iron overload diseases is variably modulated by circulating factors. PLoS ONE 7(5):e36425

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Hendy O, Allam M, Allam A, Attia M, El ST, Eldin M et al (2010) Hepcidin levels and iron status in beta-thalassemia major patients with hepatitis C virus infection. Egypt J immunol 17(2):33–44

    PubMed  Google Scholar 

  29. Aboul-Enein A, Amal E-B, Hamdy M, Shaheen I, El-Saadany Z, Samir A et al (2015) Peripheral expression of hepcidin gene in Egyptian β-thalassemia major. Gene 564(2):206–209

    CAS  PubMed  Google Scholar 

  30. Khaled A, Ezzat DA, Salem HA, Seif HM, Rabee H (2019) Effective method of evaluating myocardial iron concentration in pediatric patients with thalassemia major. J Blood Med 10:227

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Ansari S, Azarkeivan A, Miri-Aliabad G, Yousefian S, Rostami T (2017) Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior. Casp J Intern Med 8(3):159

    Google Scholar 

  32. Modell B, Khan M, Darlison M (2000) Survival in β-thalassaemia major in the UK: data from the UK thalassaemia register. Lancet 355(9220):2051–2052

    CAS  PubMed  Google Scholar 

  33. Nemeth E (2013) Hepcidin and β-thalassemia major. Blood J Am Soc Hematol 122(1):3–4

    CAS  Google Scholar 

  34. Longo F, Zecchina G, Sbaiz L, Fischer R, Piga A, Camaschella C (1999) The influence of hemochromatosis mutations on iron overload of thalassemia major. Haematologica 84(9):799–803

    CAS  PubMed  Google Scholar 

  35. Sharma V, Panigrahi I, Dutta P, Tyagi S, Choudhry VP, Saxena R (2007) HFE mutation H63D predicts risk of iron over load in thalassemia intermedia irrespective of blood transfusions. Indian J Pathol Microbiol 50(1):82–85

    PubMed  Google Scholar 

  36. Nemeth E, Ganz T (2006) Hepcidin and iron-loading anemias. Haematologica 91(6):727–732

    CAS  PubMed  Google Scholar 

  37. Kearney SL, Nemeth E, Neufeld EJ, Thapa D, Ganz T, Weinstein DA et al (2007) Urinary hepcidin in congenital chronic anemias. Pediatr Blood Cancer 48(1):57–63

    PubMed  Google Scholar 

  38. Kemna E, Tjalsma H, Laarakkers C, Nemeth E, Willems H, Swinkels D (2005) Novel urine hepcidin assay by mass spectrometry. Blood 106(9):3268–3270

    CAS  PubMed  Google Scholar 

  39. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I et al (2002) The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Investig 110(7):1037–1044

    CAS  PubMed  Google Scholar 

  40. Kattamis A, Papassotiriou I, Palaiologou D, Apostolakou F, Galani A, Ladis V et al (2006) The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica 91(6):809–812

    CAS  PubMed  Google Scholar 

  41. Pasricha S-R, Frazer DM, Bowden DK, Anderson GJ (2013) Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study. Blood J Am Soc Hematol 122(1):124–133

    CAS  Google Scholar 

  42. Haghpanah S, Esmaeilzadeh M, Honar N, Hassani F, Dehbozorgian J, Rezaei N et al (2015) Relationship between serum hepcidin and ferritin levels in patients with thalassemia major and intermedia in Southern Iran. Iran Red Crescent Med J 17(7):e28343

    PubMed  PubMed Central  Google Scholar 

  43. Papanikolaou G, Tzilianos M, Christakis JI, Bogdanos D, Tsimirika K, MacFarlane J et al (2005) Hepcidin in iron overload disorders. Blood 105(10):4103–4105

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Wish JB (2006) Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 1(Supplement 1):S4–S8

    CAS  PubMed  Google Scholar 

  45. Tang MY, Chen TW, Zhang XM, Huang XH (2014) GRE T2-weighted MRI: principles and clinical applications. BioMed Res Int. https://doi.org/10.1155/2014/312142

    Article  PubMed  PubMed Central  Google Scholar 

  46. Said Othman KM, Elshazly SA, Heiba NM (2014) Role of non-invasive assessment in prediction of preclinical cardiac affection in multi-transfused thalassaemia major patients. Hematology 19(7):380–387

    CAS  PubMed  Google Scholar 

  47. Bartnikas TB, Fleming MD (2010) A tincture of hepcidin cures all: the potential for hepcidin therapeutics. J Clin Investig 120(12):4187–4190

    CAS  PubMed  Google Scholar 

  48. Gardenghi S, Ramos P, Marongiu MF, Melchiori L, Breda L, Guy E et al (2010) Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice. J Clin Investig 120(12):4466–4477

    CAS  PubMed  Google Scholar 

  49. Ramos E, Ruchala P, Goodnough JB, Kautz L, Preza GC, Nemeth E et al (2012) Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood J Am Soc Hematol 120(18):3829–3836

    CAS  Google Scholar 

  50. Katsarou A, Pantopoulos K (2018) Hepcidin therapeutics. Pharmaceuticals 11(4):127

    CAS  PubMed Central  Google Scholar 

  51. Corradini E, Schmidt PJ, Meynard D, Garuti C, Montosi G, Chen S et al (2010) BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice. Gastroenterology 139(5):1721–1729

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Rivera S, Nemeth E, Gabayan V, Lopez MA, Farshidi D, Ganz T (2005) Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood 106(6):2196–2199

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Morán-Jiménez MJ, Méndez M, Santiago B, Rodríguez‐García ME, Moreno‐Carralero MI, Sánchez‐Lucío AC et al (2010) Hepcidin treatment in Hfe–/– mice diminishes plasma iron without affecting erythropoiesis. Eur J Clin Invest 40(6):511–517

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mashhad University of Medical Sciences, Mashhad, Iran

    Hossein Ayatollahi, Seyedeh Fatemeh Mousavi Nezhad & Zahra Badiei

  2. Birjand University of Medical Sciences, Birjand, Iran

    Amir Talebpour

  3. Gonabad University of Medical Sciences, Gonabad, Iran

    Hossein Nezami

Authors
  1. Hossein Ayatollahi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seyedeh Fatemeh Mousavi Nezhad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amir Talebpour
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zahra Badiei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hossein Nezami
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Seyedeh Fatemeh Mousavi Nezhad.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ayatollahi, H., Mousavi Nezhad, S.F., Talebpour, A. et al. Relation of hepcidin gene expression in blood mononuclear cells with iron overload severity among β-thalassemia major patients. Mol Biol Rep 47, 9353–9359 (2020). https://doi.org/10.1007/s11033-020-06012-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-020-06012-2

Keywords

Search

Navigation